Merck & Co Receive $700 Million From Blackstone to Boost Cancer Drug Development

By
Rihem Akkouche
-
0
47

  • Up to $2 billion for a China-developed cardiovascular therapy.

  • More than $1 billion for a Yale cancer research spinoff.

  • Up to $3 billion for an eye-disease biotech.

Shaping the Future of Oncology

While counsel information for the Blackstone deal was not immediately available, industry observers say the partnership underscores the increasing fusion of Wall Street capital with scientific innovation—a trend redefining how life-saving therapies move from lab to market.

With this $700 million infusion, Merck & Co. positions itself at the forefront of next-generation oncology, betting that sac-TMT could become a cornerstone in its battle against some of the world’s deadliest cancers.